Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now ...

The FDA has placed a partial clinical hold on Novartis’ recently-approved gene therapy Zolgensma for spinal muscular atrophy (SMA), after animal studies pointed to a possible risk with the drug. In a ...

The open-label trial enrolled patients aged between two and 12 years who have a clinical diagnosis of Dravet syndrome.

Study examines Qalsody safety after approval “This study is the first to systematically conduct a post-marketing [safety] ...

Blood-brain barrier drug delivery reached a landmark: the FDA’s March 2026 accelerated approval of Denali Therapeutics’ ...

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over the course of 18 months.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living ...

Biogen Inc. (NASDAQ:BIIB) traded higher after releasing encouraging Phase 2 data for its experimental Alzheimer’s treatment, ...

MarketBeat Week in Review – 05/18 - 05/22 Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early ...

Alzheimer's Association International Conference (AAIC Meeting) 2026 July 12, 2026 11:15 AM EDTCompany ParticipantsTim Power - Head ...

The Phase I/II trial will enroll pediatric patients with the seizure-causing condition who will be dosed every six months.

Researchers are exploring delivering super-specific AAVs through the brain's natural waste disposal system, which can carry ...